[News Brief] Daewoong Pharma Partners for Dupilumab Biosimilar Development
South Korea-based Daewoong Pharmaceutical has partnered with China-based Chime Biologics to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent.…
South Korea-based Daewoong Pharmaceutical has partnered with China-based Chime Biologics to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent.…
The US Food and Drug Administration (FDA) has approved a label expansion for Tremfya (guselkumab) to include evidence for inhibition…
Pfizer has received US Food and Drug Administration (FDA) approval for an expanded indication of Hympavzi (marstacimab-hncq) for adults and…
Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co. for the development, registration and commercialisation…
PharmaEssentia Corporation has received approval from Taiwan’s Ministry of Health and Welfare for Besremi (ropeginterferon alfa-2b) for the treatment of…
Formosa Pharmaceuticals, Inc. has entered into an exclusive licensing agreement with Samil Pharmaceutical Co., Ltd. for the commercialisation of an…
Simcere Pharmaceutical Group Limited has entered a research collaboration with Stanford University School of Medicine to develop potential treatments for…
Guangdong Zhenjiankang Medical Technology Development Co., Ltd. has passed the Hong Kong Stock Exchange Main Board listing hearing under Chapter…
Metis TechBio Co Ltd has completed an initial public offering in Hong Kong, raising more than HK$2.1 billion to support…
Mabwell has completed a dual primary listing on the Main Board of the Hong Kong Stock Exchange following its earlier…